S003 Cutaneous Lupus and Dermatomyositis: Management Pearls and Pitfall for the General Dermatologist
DESCRIPTION
A case-based approach will be utilized to describe practical clinical scenarios that will enable the resident or general dermatologist to appropriately diagnose and manage patients with cutaneous lupus erythematosus and dermatomyositis. The importance of a thorough and intentional clinical examination will be emphasized to help participants build confidence in accurately diagnosing these relatively rare and often challenging to diagnose conditions. Participants will learn to develop treatment algorithms incorporating typical modalities such as sun protection, topical therapies, and antimalarials, as well as other systemic medications. The evidence for the effectiveness of these agents and their safe use in adults and children will be reviewed. Participants will be able to identify when to initiate systemic immunosuppressive therapy and/or refer to other specialists. Participants will also develop a strategy to appropriately work-up these potentially systemic conditions. Complex cases will also be reviewed.
LEARNING OBJECTIVES
Utilize clinical examination to aid in accurate diagnosis of patients with cutaneous lupus erythematosus and dermatomyositis.
Develop a treatment strategy for cutaneous lupus and cutaneous dermatomyositis that incorporates modalities including sun protection, topical therapies, and systemic medications.
Describe associated systemic complications of cutaneous lupus and dermatomyositis and screen appropriately for them.
SCHEDULE
9:00 AM
Introduction
Christopher T. Richardson, PhD, MD, FAAD
9:05 AM
Cutaneous lupus (diagnosis, systemic evaluation, etc.)
John R. Edminister, MD, FAAD
9:30 AM
Cutaneous lupus (treatment)
Allen Wayne Ho, MD, PhD, FAAD
9:55 AM
Cutaneous lupus - Q&A
10:00 AM
Dermatomyositis (diagnosis, phenotypes)
Christopher T. Richardson, PhD, MD, FAAD
10:25 AM
Dermatomyositis (evaluation, management)
Avery H. LaChance, MPH, MD, FAAD
10:55 AM
Dermatomyositis - Q&A
11:00 AM
Challenging cases
Jeffrey R. Gehlhausen, MD, PhD, FAAD
11:20 AM
Challenging cases
11:40 AM
Q&A
DIRECTOR
Alisa Femia, MD, FAAD
SPEAKERS
John R. Edminister, MD, FAAD
Wake Forest School of Medicine
Jeffrey R. Gehlhausen, MD, PhD, FAAD
Yale Department of Dermatology and Dermatopathology
Allen Wayne Ho, MD, PhD, FAAD
Avery H. LaChance, MPH, MD, FAAD
Mass General Brigham Dermatology
Joshua Prenner, MD
Christopher T. Richardson, PhD, MD, FAAD
DISCLOSURES
John R. Edminister, MD, FAAD
Hyloris Pharmaceuticals – Investigator(Grants/Research Funding); Priovant Therapeutics – Consultant (1099 relationship)(Fees); Wake Forest University Health Sciences – Employee (w-2 relationship)(Patent royalties or other compensation for Intellectual Property Rights); WebMD – Speaker(Fees);
Alisa Femia, MD, FAAD
No financial relationships exist with ineligible companies.
Jeffrey R. Gehlhausen, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Allen Wayne Ho, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Avery H. LaChance, MPH, MD, FAAD
atheneum – Consultant (1099 relationship)(Fees); Biogen – Advisory Board(Fees); Guidepoint Global, LLC – Consultant (1099 relationship)(Fees); Johnson & Johnson Consumer, Inc. – Advisory Board(Honoraria); MEDACorp – Consultant (1099 relationship)(Fees); Merck – Investigator(Grants/Research Funding); Pfizer Inc. – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Priovant Therapeutics – Advisory Board(Fees); TD Cowen – Speaker(Honoraria);
Joshua Prenner, MD
No financial relationships exist with ineligible companies.
Christopher T. Richardson, PhD, MD, FAAD
AstraZeneca – Investigator(Grants/Research Funding); Biogen – Advisory Board(Fees); Immunovant – Consultant (1099 relationship)(Fees); Incyte Corporation – Investigator(Grants/Research Funding); Merck – Consultant (1099 relationship)(Fees); Priovant – Advisory Board(Honoraria); Ribon Therapeutics – Investigator(Grants/Research Funding);